

A2. 33. The pharmaceutical agent of claim 31 wherein the therapeutically effective amount of a material comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.

A3 35. The pharmacological agent of claim 33 wherein said amyloid disease for treatment is selected from the group of amyloid diseases associated with Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, the amyloidosis associated with type II diabetes, the amyloidosis associated with chronic inflammation, various forms of malignancy and Familial Mediterranean Fever, the amyloidosis associated with multiple myeloma and other B-cell dyscrasias, the amyloidosis associated with the prion diseases including Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru and animal scrapie, the amyloidosis associated with long-term hemodialysis and carpal tunnel syndrome, and the amyloidosis associated with endocrine tumors such as medullary carcinoma of the thyroid, and the alpha-synuclein associated disease is selected from Parkinson's disease and Lewy body disease.

Please add new Claim 39 as follows:

A4 39. The pharmacological agent of claim 35 wherein the disease related to alpha-synuclein is Parkinson's disease.

REMARKS

Claims 1 - 38 are pending the application; by this Amendment Claims 2-7, 9, 14-17, 19-21, 23-30 and 32 have been canceled, Claims 31, 33 and 35 have been amended, and new claim 39 has been added. These amendments and new claim add no new matter to the application.

The Examiner has identified seven species: I (Claims 1-18, 22); II (Claim 19); III (Claims 20-21); IV (Claim 23); V (Claims 24-30); VI (Claims 31 and 33-38); and VII (Claims 32-38). Applicant herewith elects species VI (Claims 31 and 33-38) for examination on the merits.